“an increasing trend”

Although no significant differences were observed, an increasing trend with age was noted ( p = 0.156, Figure 1B ).

Post hoc Bonferroni showed that EphB1‐3 receptor protein levels of MIA offspring had an increasing trend at PND45 ( p = 0.1575) but an obvious increase at PND65 compared with the control groups ( p = 0.0152) (Figure 4E ).

In contrast, an increasing trend of 20.9% to 26.7% ( p = 0.16) and a significantly increasing trend of 27.4% to 41.3% ( p = 0.0021) were observed for ATX and GXR, respectively.

Although it seems that there is an increasing trend across the years, the data are not statistically significant, potentially due to wide confidence intervals (χ 2 = 6.59; df = 4; P = 0.16).

The values of hs -CRP showed an increasing trend that did not reach significance (P = 0.16).

After nystatin treatment, the expression of IL-4 exhibited an increasing trend (treated group vs. untreated 15 d sub-group, 10.67 ± 2.066 vs. 8.17 ± 3.488, respectively, P = 0.162).

The complication rates showed an increasing trend in order to S-ReSC score groups (1.87% [14/75] vs. 28.6% [12/42] vs. 34.2% [13/38], respectively; p = 0.166).

4 A), and the number of muscle fibres per unit area showed an increasing trend at 1 d of age ( P = 0.167, Fig. 3 B).

Fertilization rates showed an increasing trend (F 2,12 = 2.03; p = 0.17) as the dose of E 2 increased ( Fig 6 ).

At Day 14 the placebo drove an increasing trend in perceived malodor (median change = +20%; p = 0.17, one-tailed paired Wilcoxon test), whereas perceived malodor for the COHP group did not change (median change = 0%; p = 0.29, one-tailed paired Wilcoxon test).

Similarly, the maximum neointimal thickness showed an increasing trend (0.7–0.8 mm, p = 0.17).

We observed significant increase in DPT cell absolute numbers (cisplatin 231.8 ± 51.72 vs control 92.50 ± 35.44, P ≤ 0.01) and an increasing trend in the percentage (cisplatin 0.40 ± 0.14% vs control 0.16 ± 0.03%, P = 0.17) in cisplatin treated mice compared to vehicle control mice at 72 h (Fig. 6 A).

An increasing trend in the frequency of PTEN protein loss has been observed in men ( p = 0.171) with metastases to regional lymph nodes ( p = 0.263), in stage IV ( p = 0.250), and in patients with positive smoking status ( p = 0.055) ( Table 1 ).

The beta-cell area showed an increasing trend ( P = 0.173), whereas the alpha-cell area remained unchanged following dapagliflozin treatment [Figure 2 D−F].

Results Effects of LPS on IL-6 concentration LPS-treated mice showed a significant increase in IL-6 concentration in the serum ( Fig 3A ) (p = 0.0002) and an increasing trend in the supernatant of the brain tissue, i . e ., the cerebral cortex, including the ACC ( Fig 3B ) (p = 0.177).

Additionally, there was an increasing trend in the abundance of Lactobacillaceae ( p = 0.18) and Bifidobacteriaceae after L. reuteri DYNDL22M62 treatment.

An increasing trend in brain-derived neurotrophic factor (BDNF) levels was observed (1.32-fold, adjusted p = 0.18), which may support previous evidence of fasting's neuroprotective effects [ 14 ].

In the current study, although the crude comparison was non-significant, there was an increasing trend of mortality in combination therapy (20/75 (26.6%) vs. 17/94 (18.1%), p = 0.180).

Skin hydration on the cheek had an increasing trend with probiotic supplementation ( Figure 3 , p = 0.18) but not with placebo.

An increasing trend in the abundance of Firmicutes and the Firmicutes/Bacteroidetes ratio (F/B ratio) was observed in the FMT-TD group compared to the CON group ( p = 0.180) (Supplementary Fig. 1d ; Fig. 2e ).

cloacae in COPD and asthma, there was an increasing trend of 0.20 SMD ( P = 0.18).

On the whole, Prevotella showed a decreasing trend ( P = 0.18), Neisseria showed an increasing trend ( P = 0.34), Capnocytophaga decreased at first and then increased, while Leptotrichia showed little change.

There was an increasing trend in 6MWT when training weeks increased from 7 to 12 ( P = 0.18, coefficient = 5.04, 95% CI − 2.93–13.02) and training frequency increased from 1.5 (average) to 7 times per week ( P = 0.34, coefficient = 3.30, 95% CI − 4.16–10.76) (see Supplementary Figs.

Even if there is an increasing trend ( p = 0.1822 for cortical porosity) of bone loss in the nefopam group compared to the control group, cortical porosity and bone volume/total volume (BV/TV) were not different between the two groups ( Figures 3B,C ).

Although average July temperatures also recorded an increasing trend, this was not significant ( R 2 = .050, F = 1.825, p = .185).